TNFRSF1A and Parkinson disease: Third, Mendelian randomization estimates relate to an averaged effect of long-term exposure to the TNF-TNFR1 inhibitors across the life course; therefore, a null result may reflect either a true lack of an overall effect on PD risk at any stage of life or a sum of opposing, period-specific effects that balance out in our models.